Vetenskapliga publikationer

Risk for having low visual acuity after 1 and 2 years of treatment with ranibizumab or bevacizumab for patients with neovascular age-related macular degeneration.
Westborg I, Albrecht S, Rosso A.
Retina. 2017 Jan 30. doi: 10.1097/IAE.0000000000001431. [Epub ahead of print]

Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration, a population- and register-based study from northern Sweden
Elisabet Granstam, Inger Westborg, Anna Barkander, Malin Börjesson, Sara Lindahl, Eva Meszaros, Anna Wojciechowska-Zajac, Philippe Wagner,
Susanne Albrecht, Niklas Karlsson, Gunilla Bjärnhall, and Monica Lovestam-Adrian.
Acta Ophthalmologica 2016.

Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration.
Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M, Cheung G, Haller J, Johnston R, Kim R, Klaver C, McKibbin M, Ngah NF, Pershing S, Shankar D, Tamura H, Tufail A, Weng CY, Westborg I, Yelf C, Yoshimura N, Gillies MC.
Am J Ophthalmol. 2016 Aug;168:1-12. doi: 10.1016/j.ajo.2016.04.012.

Publicerad: 17 november 2014
Senast uppdaterad: 21 februari 2017